

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

1. (currently amended) A method for treating ~~pain~~ headache ~~in a subject~~ comprising administering to ~~said~~ a subject in need of headache relief, an effective amount of a compound selected from the group consisting of loxapine, pharmaceutically acceptable salts of loxapine, and prodrugs of loxapine.
- 2.-4. (cancelled)
5. (currently amended) A method in accordance with ~~claim 4~~ claim 1, wherein said ~~pain~~ headache is a migraine ~~pain~~ headache.
6. (currently amended) A method in accordance with ~~claim 4~~ claim 1, wherein said ~~pain~~ headache is a cluster headache ~~pain~~.
7. (currently amended) A method in accordance with ~~claim 4~~ claim 1, wherein said ~~pain~~ headache is a tension-type headache ~~pain~~.
8. (currently amended) A method in accordance with claim 1, wherein said compound is administered by inhalation.
9. (currently amended) A method in accordance with claim 1, wherein said subject is human, said ~~pain~~ headache is a migraine headache, and said compound is administered by inhalation.
10. (previously presented) A method in accordance with claim 1, wherein from about 0.3 to about 20 mg of loxapine is administered, or an amount of a salt or prodrug of loxapine is

administered that produces in the subject a blood concentration of loxapine equivalent to the administration of from about 0.3 to about 20 mg of loxapine.

11. (currently amended) A method in accordance with claim ~~4~~ 10, wherein from about 1 to about 10 mg of loxapine is administered, or an amount of a salt or prodrug of loxapine is administered that produces in the subject a blood concentration of loxapine equivalent to the administration of from about 1 to about 10 mg of loxapine.

12. (currently amended) A method in accordance with claim ~~10-1~~, wherein ~~administration of the loxapine or salt or prodrug thereof to the subject is conducted~~ the compound is formulated so as to result in a maximum blood level of loxapine within about 30 minutes from ~~said~~ administration.

13. (currently amended) A method in accordance with claim ~~10 1~~, wherein ~~administration of the loxapine or salt or prodrug thereof to the subject is conducted~~ the compound is formulated so as to result in a maximum blood level of loxapine within about 15 minutes from ~~said~~ administration.

14. (currently amended) A method in accordance with claim ~~10 1~~, wherein ~~administration of the loxapine or salt or prodrug thereof to the subject is conducted~~ the compound is formulated so as to result in a peak rate of increase in the blood level of loxapine of at least about 1 ng/ml/minute.

15. (currently amended) A method in accordance with claim ~~10 1~~, wherein ~~administration of the loxapine or salt or prodrug thereof to the subject is conducted~~ the compound is formulated so as to result in a blood level of loxapine of at least about 5 ng/ml within about 15 minutes from ~~said~~ administration.

16. (currently amended) A method in accordance with claim 1, wherein said compound is administered via inhalation using a rapid-heating drug delivery article or a thin-film drug delivery article.

17. (currently amended) A method in accordance with claim 1, wherein said compound is administered via an inhalation delivery device, wherein said compound ~~being~~ is vaporized and condensed to provide at least 50% recovery of said compound in an aerosol, and wherein said aerosol contains less than about 5% by weight of compound degradation products.

18. (currently amended) A method in accordance with claim 17, wherein said compound is coated on a substrate in the delivery device as a ~~thin film having a film~~ having a thickness between about 0.5 and 20 μm .

19. (currently amended) A method in accordance with claim 1, wherein said compound is administered in the form of an aerosol having a mass median aerodynamic diameter (~~MMAD~~) of between about 0.01 and about 3 μm .

20. (currently amended) A method in accordance with claim 1, wherein said compound is administered via a rapid heating drug delivery article, and wherein said compound ~~being~~ is volatilized from a compound composition film under conditions sufficient to provide an aerosol having at least 50% recovery of said compound and containing less than about 10% by weight of compound degradation products.

21. (withdrawn) A composition for the treatment of pain, said composition comprising (a) an analgesic amount of a compound selected from the group consisting of loxapine, pharmaceutically acceptable salts thereof, and prodrugs thereof, and (b) a pharmaceutically acceptable carrier.

22. (withdrawn) A composition of claim 21, further comprising one or more analgesic, anti-inflammatory or antimigraine agents.

23. (withdrawn) A thin-film composition for the treatment of pain comprising an analgesic amount of a compound selected from the group consisting of loxapine, pharmaceutically acceptable salts thereof and prodrugs thereof, and having a film thickness of from about 0.5 to about 20 μm .

24. (original) A method for treating headache pain in a subject comprising administering to said subject an effective amount of a compound selected from the group consisting of loxapine, pharmaceutically acceptable salts of loxapine and prodrugs of loxapine.